Sestrin 1 ameliorates cardiac hypertrophy via autophagy activation. Issue 6 (9th February 2017)

• Record Type: Journal Article
• Authors: Xue, Ruicong; Zeng, Junyi; Chen, Yili; Chen, Cong; Tan, Weiping; Zhao, Jingjing; Dong, Bin; Sun, Yu; Dong, Yugang; Liu, Chen
• Is Part Of: Journal of cellular and molecular medicine. Volume 21:Issue 6(2017)
• Page Start: 1193
• Page End: 1205
• Publication Date: 2017-02-09
• Subjects: Sestrin 1 -- cardiac hypertrophy -- phenylephrine -- autophagy -- AMPK; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13052
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Cardiac hypertrophy is one of the major risk factors of cardiovascular morbidity and mortality. Autophagy is acknowledged to be an important mechanism regulating cardiac hypertrophy. Sestrin 1, a downstream target gene of p53, has been proven to regulate autophagy. However, the role of Sestrin 1 in cardiac hypertrophy remains unknown. Our study showed that Sestrin 1 mRNA and protein expression declined in pressure overload cardiac hypertrophy and phenylephrine (PE)‐induced cardiac hypertrophy. Knockdown of Sestrin 1 by RNAi deteriorated PE‐induced cardiac hypertrophy, whereas the overexpression of Sestrin 1 by adenovirus transfection blunted hypertrophy. We discovered that knockdown of Sestrin 1 resulted in impaired autophagy while overexpression of Sestrin 1 resulted in increased autophagy without affecting lysosomal function. In addition, the antihypertrophic effect of Sestrin 1 overexpression was eliminated by autophagy blockade. Importantly, Sestrin 1 targets at the AMPK/mTORC1/autophagy pathway to inhibit cardiac hypertrophy by interaction with AMPK which is responsible for autophagy regulation. Taken together, our data indicate that Sestrin 1 regulates AMPK/mTORC1/autophagy axis to attenuate cardiac hypertrophy.